Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>Management is not aware of any significant reason for the recent unusual price movement in <a href="https://www.smartkarma.com/entities/austar-lifesciences-ltd" target="_blank" data-smartkarma-citation="entities:9599:1" rel="noopener">Austar Lifesciences (6118 HK)</a> shares.</li>
<li>The company’s strong financial performance in H1 2021 and order book seems to be mostly driven by the COVID-19 vaccine-related demand, which is expected to fade off this year.</li>
<li>Divestment of its 60% equity interest in Pall-Austar Lifesciences is expected to weaken its competitive positioning in the lifescience tool market in China.</li>
</ul>


Management is not aware of any significant reason for the recent unusual price movement in Austar Lifesciences (6118 HK) shares.
The company’s strong financial performance in H1 2021 and order book seems to be mostly driven by the COVID-19 vaccine-related demand, which is expected to fade off this year.
Divestment of its 60% equity interest in Pall-Austar Lifesciences is expected to weaken its competitive positioning in the lifescience tool market in China.


Austar Lifesciences (6118 HK): It's Risky to Catch the Falling Knife

China

Austar Lifesciences Limited provides integrated engineering solutions with services and products for pharmaceutical manufacturers and research institutes in China and other emerging countries. The Company also manufactures, sells and distributes pharmaceutical equipment and life science consumables.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Austar Lifesciences (6118 HK): It's Risky to Catch the Falling Knife

Despite the recent price correction, Austar Lifesciences does not seem to be an attractive long-term investable idea, given the low float and...

Tina Banerjee